The mechanism of sirtuin 2–mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease

Sirtuin genes have been associated with aging and are known to affect multiple cellular pathways. Sirtuin 2 was previously shown to modulate proteotoxicity associated with age-associated neurodegenerative disorders such as Alzheimer and Parkinson disease (PD). However, the precise molecular mechanisms involved remain unclear. Here, we provide mechanistic insight into the interplay between sirtuin 2 and α-synuclein, the major component of the pathognomonic protein inclusions in PD and other synucleinopathies. We found that α-synuclein is acetylated on lysines 6 and 10 and that these residues are deacetylated by sirtuin 2. Genetic manipulation of sirtuin 2 levels in vitro and in vivo modulates the levels of α-synuclein acetylation, its aggregation, and autophagy. Strikingly, mutants blocking acetylation exacerbate α-synuclein toxicity in vivo, in the substantia nigra of rats. Our study identifies α-synuclein acetylation as a key regulatory mechanism governing α-synuclein aggregation and toxicity, demonstrating the potential therapeutic value of sirtuin 2 inhibition in synucleinopathies.

[1]  Ruben Abagyan,et al.  Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease , 2007, Science.

[2]  Lei Zhang,et al.  The role of autophagy in Parkinson's disease , 2012, Behavioral and Brain Functions.

[3]  A. Cuervo,et al.  Autophagy gone awry in neurodegenerative diseases , 2010, Nature Neuroscience.

[4]  S. Kügler,et al.  Neuron-Specific Expression of Therapeutic Proteins: Evaluation of Different Cellular Promoters in Recombinant Adenoviral Vectors , 2001, Molecular and Cellular Neuroscience.

[5]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[6]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Outeiro,et al.  The sour side of neurodegenerative disorders: the effects of protein glycation , 2010, The Journal of pathology.

[8]  C. Ayata,et al.  The Sirtuin-2 Inhibitor AK7 Is Neuroprotective in Models of Parkinson’s Disease but Not Amyotrophic Lateral Sclerosis and Cerebral Ischemia , 2015, PloS one.

[9]  Michele Vendruscolo,et al.  Direct Observation of the Three Regions in α-Synuclein that Determine its Membrane-Bound Behaviour , 2014, Nature Communications.

[10]  S. Kügler,et al.  Long-term rescue of a lethal inherited disease by adeno-associated virus-mediated gene transfer in a mouse model of molybdenum-cofactor deficiency. , 2007, American journal of human genetics.

[11]  Elizabeth M. Tomkinson,et al.  The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. , 2011, Human molecular genetics.

[12]  S. Kügler,et al.  Potentiation of in vivo neuroprotection by BclXL and GDNF co-expression depends on post-lesion time in deafferentiated CNS neurons , 2006, Gene Therapy.

[13]  A. Ciechanover,et al.  Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology , 2013, Proceedings of the National Academy of Sciences.

[14]  Philipp Selenko,et al.  Structural disorder of monomeric α-synuclein persists in mammalian cells , 2016, Nature.

[15]  Ad Bax,et al.  Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. , 2009, Journal of molecular biology.

[16]  F. Blandini,et al.  Role of Autophagy in Parkinson's Disease. , 2019, Current medicinal chemistry.

[17]  S. Becker,et al.  Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation , 2014, Nature Communications.

[18]  D. Penque,et al.  Heat‐mediated enrichment of α‐synuclein from cells and tissue for assessing post‐translational modifications , 2013, Journal of neurochemistry.

[19]  J. Schulz,et al.  A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice , 2012, Neurobiology of Disease.

[20]  Martin Strohalm,et al.  mMass 3: a cross-platform software environment for precise analysis of mass spectrometric data. , 2010, Analytical chemistry.

[21]  G. Braus,et al.  Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation , 2014, PLoS genetics.

[22]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[23]  D. Selkoe,et al.  N-Alpha-Acetylation of α-Synuclein Increases Its Helical Folding Propensity, GM1 Binding Specificity and Resistance to Aggregation , 2014, PloS one.

[24]  Ian F. Harrison,et al.  The Discovery of a Highly Selective 5,6,7,8‐Tetrahydrobenzo[4,5]thieno[2,3‐d]pyrimidin‐4(3H)‐one SIRT2 Inhibitor that is Neuroprotective in an in vitro Parkinson’s Disease Model , 2015, ChemMedChem.

[25]  J. Schulz,et al.  Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice , 2013, Neurobiology of Aging.

[26]  S. Tenreiro,et al.  PLK2 Modulates α-Synuclein Aggregation in Yeast and Mammalian Cells , 2013, Molecular Neurobiology.

[27]  F. Alt,et al.  SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. , 2006, Genes & development.

[28]  R. M. de Oliveira,et al.  SIRT2 as a Therapeutic Target for Age-Related Disorders , 2012, Front. Pharmacol..

[29]  H. Choi,et al.  SIRT2 interferes with autophagy-mediated degradation of protein aggregates in neuronal cells under proteasome inhibition , 2012, Neurochemistry International.

[30]  E. Masliah,et al.  A Pathologic Cascade Leading to Synaptic Dysfunction in α-Synuclein-Induced Neurodegeneration , 2010, The Journal of Neuroscience.

[31]  D. Stewart,et al.  (Poly)phenols protect from α-synuclein toxicity by reducing oxidative stress and promoting autophagy. , 2015, Human molecular genetics.

[32]  Hui Zhang,et al.  Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity , 2010, Nature Cell Biology.

[33]  Wei-Guo Zhu,et al.  Anti-neoplastic activity of the cytosolic FoxO1 results from autophagic cell death , 2010, Autophagy.

[34]  Jasper Akerboom,et al.  β‐synuclein aggregates and induces neurodegeneration in dopaminergic neurons , 2013, Annals of neurology.

[35]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[36]  C. Griesinger,et al.  Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  HighWire Press.  The journal of neuroscience : the official journal of the Society for Neuroscience. , 1981 .

[38]  B. Hyman,et al.  α-Synuclein–enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons , 2001, Neuroscience.

[39]  Jeffrey N. Savas,et al.  Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation , 2009, Cell.

[40]  S. Imai,et al.  Systemic regulation of mammalian ageing and longevity by brain sirtuins , 2014, Nature Communications.

[41]  H. Lashuel,et al.  Semisynthesis and Enzymatic Preparation of Post-translationally Modified α-Synuclein. , 2016, Methods in molecular biology.

[42]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[43]  G. Donmez,et al.  SIRT1 and SIRT2: emerging targets in neurodegeneration , 2013, EMBO molecular medicine.

[44]  R. Abagyan,et al.  Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. , 2007, Science.

[45]  T. Outeiro,et al.  Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. , 2013, Journal of Parkinson's disease.

[46]  M. Beal,et al.  Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. , 2005, Current drug targets. CNS and neurological disorders.

[47]  L. Guarente,et al.  SIRT1 deacetylates and positively regulates the nuclear receptor LXR. , 2007, Molecular cell.

[48]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[49]  G. Halliday,et al.  LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models , 2012, Journal of Molecular Medicine.

[50]  H. Budka,et al.  An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology , 2012, Acta Neuropathologica.

[51]  Dorte B. Bekker-Jensen,et al.  Proteomic Analysis of Lysine Acetylation Sites in Rat Tissues Reveals Organ Specificity and Subcellular Patterns , 2012, Cell reports.

[52]  F. Giorgini,et al.  Glycation potentiates neurodegeneration in models of Huntington’s disease , 2016, Scientific Reports.